DUETACT*
Manufacturer Details
TAKEDA PHARMACEUTICALS INC
Takeda pharmaceuticals America Inc
Compositions:
Pioglitazone 30mg ,
Glimepiride 2mg/4mg tablets in 30s and 90s pack,
|
Strength
|
Rate
|
Packing Style
|
|
30mg+ 2mg/4mg tabs
|
0.00
|
in 30s and 90s pack
|
List of Related Indications:
- Type II Diabetes not respons to diet
List Of Drugs:
- Pioglitazone Hydrochloride + Glimepiride - Antidiabetic Combination Product
Indication Type Description:
Indication:
Type II Diabetes not responsive to diet
Dosages/ Overdosage Etc:
Indication-
Type II Diabetes not responsive to diet
Dosage-
Maximum dose - pioglitazone 45mg/glimepiride 8mg per day.
Elderly- initial dose dosing, dose increments and maintenance dose should be conservative to
avoid hypoglycemic reactions. The initial dose should be started at glimepride 1mg prior to
prescribing pioglitazone/glimepride.
Renal function impairment- the initial starting dose at glimepride 1mg prior to prescribing
pioglitazone/glimepride,.
Hepatic function impairment- the dose dose should be started at glimepride 1mg prior to
prescribing pioglitazone/glimepride,
Debilated /malnourished patients.- the initial starting dose at glimepride 1mg prior to prescribing
pioglitazone/glimepride,.
Congestive heart failure and hypertension- the lowest approved dose of pioglitazone/glimepride
therapy should be prescribed
Administration- once daily with the first meal of the day
